Novartis bid to revive multiple sclerosis drug Gilenya patent rebuffed by US Supreme Court Ruchika Sharma18 April 2023 7:00 AM GMTThe USFDA in 2010 approved Gilenya to treat relapsing forms of multiple sclerosis.
Roche flags 2023 earnings decline on slump in COVID products Ruchika Sharma3 Feb 2023 5:51 AM GMTAnalysts have said that market confidence in Roche's drug development abilities, previously among the highest in the industry, has taken a blow from...
US Supreme Court turns down Novartis bid to block launch of multiple sclerosis drug Gilenya generics Ruchika Sharma15 Oct 2022 8:00 AM GMTNovartis settled with some of the drugmakers it had sued, allowing for some Gilenya generics before a key patent's 2027 expiration.
Novartis to take US drug patent case to Supreme Court Ruchika Sharma22 Sep 2022 10:16 AM GMTZurich: Novartis AG plans to ask the U.S. Supreme court to uphold the validity of a patent it holds on the dosing regimen for multiple sclerosis drug...
Whistleblower case alleging kickback for promotion of Novartis MS drug Gilenya dismissed Ruchika Sharma14 Sep 2022 9:00 AM GMTNovartis moved to dismiss, arguing that Camburn still had not offered enough detail to support his claim of a fraudulent scheme.
Setback to Novartis: US Court declares multiple sclerosis drug Gilenya patent invalid Ruchika Sharma22 Jun 2022 7:00 AM GMTNovartis also said it believes HEC and others cannot launch generic versions of Gilenya during the ongoing appeal process.
